BeOne Medicines (HKG:6160, SHA:688235) recorded an attributable profit of $95.6 million yuan in the first half of 2025, compared with an attributable loss of $371.6 million a year prior, a Thursday filing with the Hong Kong bourse said.

Earnings per share stood at $0.07 in the six months, while the company had incurred a loss per share of $0.27 in the corresponding period of the last year.

Revenue rose 45% to $2.41 billion in the half year from $1.67 billion in the year-ago period.

The higher revenue was mainly due to increased sales of the firm's internally developed products BRUKINSA and tislelizumab, as well as those of in-licensed products.